William Blair Weighs in on IDEXX Laboratories, Inc.’s FY2024 Earnings (NASDAQ:IDXX)

IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report) – Equities researchers at William Blair raised their FY2024 earnings per share estimates for IDEXX Laboratories in a research note issued on Monday, February 5th. William Blair analyst R. Daniels now forecasts that the company will post earnings per share of $11.08 for the year, up from their previous estimate of $10.77. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for IDEXX Laboratories’ current full-year earnings is $11.09 per share. William Blair also issued estimates for IDEXX Laboratories’ Q1 2025 earnings at $3.13 EPS, Q2 2025 earnings at $3.26 EPS, Q3 2025 earnings at $3.18 EPS, Q4 2025 earnings at $3.22 EPS and FY2025 earnings at $12.79 EPS.

Several other equities research analysts have also recently issued reports on the company. The Goldman Sachs Group raised their target price on IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. JPMorgan Chase & Co. raised their target price on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a research note on Tuesday. Barclays raised their target price on IDEXX Laboratories from $605.00 to $655.00 and gave the stock an “overweight” rating in a research note on Tuesday. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Wednesday, December 20th. Finally, Stifel Nicolaus dropped their price objective on IDEXX Laboratories from $500.00 to $460.00 and set a “hold” rating for the company in a research note on Monday, October 30th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $591.50.

View Our Latest Stock Report on IDXX

IDEXX Laboratories Price Performance

IDXX stock opened at $573.61 on Wednesday. The business has a fifty day moving average of $539.13 and a two-hundred day moving average of $491.70. The company has a quick ratio of 1.02, a current ratio of 1.57 and a debt-to-equity ratio of 0.42. The stock has a market cap of $47.64 billion, a price-to-earnings ratio of 56.96, a price-to-earnings-growth ratio of 3.12 and a beta of 1.25. IDEXX Laboratories has a 52-week low of $372.50 and a 52-week high of $579.68.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) last posted its quarterly earnings results on Monday, February 5th. The company reported $2.32 EPS for the quarter, beating the consensus estimate of $2.12 by $0.20. The firm had revenue of $901.60 million during the quarter, compared to analysts’ expectations of $891.88 million. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter last year, the firm earned $2.05 earnings per share.

Insider Activity

In related news, CEO Jonathan Jay Mazelsky sold 7,128 shares of the business’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $513.05, for a total transaction of $3,657,020.40. Following the completion of the transaction, the chief executive officer now directly owns 79,233 shares of the company’s stock, valued at approximately $40,650,490.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Jonathan Jay Mazelsky sold 7,128 shares of the business’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $513.05, for a total transaction of $3,657,020.40. Following the completion of the transaction, the chief executive officer now directly owns 79,233 shares of the company’s stock, valued at approximately $40,650,490.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP James F. Polewaczyk sold 11,636 shares of the business’s stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $521.79, for a total value of $6,071,548.44. Following the transaction, the executive vice president now directly owns 10,050 shares of the company’s stock, valued at $5,243,989.50. The disclosure for this sale can be found here. Insiders own 2.11% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Arlington Partners LLC boosted its position in shares of IDEXX Laboratories by 233.3% during the 2nd quarter. Arlington Partners LLC now owns 50 shares of the company’s stock worth $25,000 after acquiring an additional 35 shares in the last quarter. OFI Invest Asset Management acquired a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at about $25,000. E Fund Management Hong Kong Co. Ltd. acquired a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at about $26,000. Valley National Advisers Inc. boosted its position in shares of IDEXX Laboratories by 84.6% in the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after purchasing an additional 22 shares during the period. Finally, Altshuler Shaham Ltd acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at about $26,000. 86.85% of the stock is owned by institutional investors and hedge funds.

About IDEXX Laboratories

(Get Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Further Reading

Earnings History and Estimates for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.